Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eli Lilly And Co Ends Phase II Study Of Investigational Alzheimer's Treatment Amid Abnormal Liver Tests-DJ


Friday, 14 Jun 2013 02:26am EDT 

Dow Jones reported that Eli Lilly And Co is voluntarily ending a Phase II study of an investigational once-daily treatment that aims to slow the progression of Alzheimer's disease, as liver biochemical tests came back abnormal. The pharmaceutical company said it will evaluate the data further before determining the next steps for the entire development program for the treatment--a beta secretase inhibitor known as LY2886721. Lilly said cases of abnormal liver biochemical tests in the study were identified as part of routine monitoring and that study investigators have been notified. However, Lilly also said it thinks the abnormal tests observed in the study aren't related to the beta secretase inhibitor mechanism, which the Company remains interested in developing for Alzheimer's patients. 

Company Quote

54.087
 --
25 Nov 2014